Fig. 1From: Cardiac events during treatment with proteasome inhibitor therapy for multiple myelomaBaseline cardiovascular characteristics in patients receiving proteasome inhibitor therapy. Prevalence of cardiovascular risk factors in patients who developed cardiac adverse events (cases) versus those who did not (controls)Back to article page